Press release
Opioid-Induced Bowel Dysfunction Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results | Synergy Pharmaceuticals Inc., Theravance Biopharma US, Inc.
Opioid induced constipation is the most common side-effect occur due to excessive usage of opioids. People using opioid generally suffer from delayed gastric emptying, dyspepsia, nausea and vomiting.
Download the sample report at: https://www.pharmaproff.com/request-sample/1032
The opioids act on μ, δ, and κ-opioid receptors and perform function with respect to the type of receptors. The μ and δ opioid receptors are targeted for analgesic function. The κ-opioid receptor targets to analgesic, hallucinogenic, anti-depressants, and anti-anxiety functions.
Get the detailed analysis at: https://www.pharmaproff.com/report/opioid-induced-bowel-dysfunction-therapeutics-pipeline-analysis
Some of the major companies involved in the development of therapeutic agents for the treatment of opioid-induced bowel dysfunction includes Synergy Pharmaceuticals Inc., and Theravance Biopharma Inc.
Make enquiry before purchase at: https://www.pharmaproff.com/enquiry/1032
Theravance Biopharma Inc. is involved in developing TD-1211, a μ-opioid receptor antagonist, for the treatment of opioid-induced bowel syndrome. Moreover, Synergy Pharmaceuticals Inc. is currently involved in development of SP-333, a guanylate cyclase C agonist, for the management of this medical condition.
About Us:
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.
Contact:
Pharma Proff
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@pharmaproff.com
Web: https://www.pharmaproff.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Opioid-Induced Bowel Dysfunction Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results | Synergy Pharmaceuticals Inc., Theravance Biopharma US, Inc. here
News-ID: 1705171 • Views: …
More Releases for Opioid
Rising Opioid Use For Pain Management Fuels Growth In Opioid-Induced Constipatio …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Opioid-Induced Constipation Treatment Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size for treatment of opioid-induced constipation has seen a substantial growth recently. It is expected to escalate from a solid $1.78 billion in 2024 to an impressive $1.9 billion in 2025, exhibiting…
Growing Number Of Opioid Addiction Cases: Strategic Insights Driving Opioid Use …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Opioid Use Disorder (OUD) Market Size By 2025?
The market size for opioid use disorder (OUD) has experienced a quick expansion in the past few years. The growth is projected to rise from $3.96 billion in 2024 to $4.39 billion in 2025, boasting a compound…
Key Influencer in the Opioid-Induced Constipation Treatment Market 2025: Rising …
What combination of drivers is leading to accelerated growth in the opioid-induced constipation treatment market?
The rise in opioid administration for cancer and non-cancer pain is expected to drive the growth of the opioid-induced constipation (OIC) treatment market. Opioids are commonly used for managing moderate to severe pain, but they can cause constipation. OIC treatments are vital for improving the quality of life for patients on opioids, allowing them to maintain…
Top Factor Driving Opioid Use Disorder (OUD) Market Growth in 2025: Growing Numb …
How Are the key drivers contributing to the expansion of the opioid use disorder (oud) market?
The rise in instances of opioid dependency is set to fuel the expansion of the opioid use disorder (OUD) market. Opioid dependency defines a health concern marked by habitual and uncontrolled opioid consumption which negatively impacts health. These opioids can generate feelings of bliss and relief from pain, but continued usage often results in tolerance…
What's Driving the Opioid-Induced Constipation Treatment Market 2025-2034: Risin …
What Are the Projections for the Size and Growth Rate of the Opioid-Induced Constipation Treatment Market?
The market size for treatments of constipation caused by opioids has seen robust growth lately. The forecasted growth indicates an increase from $1.78 billion in 2024 to $1.9 billion in 2025, representing a compound annual growth rate (CAGR) of 7.0%. This past growth is associated with a growing elderly population, individualized treatments for OIC, the…
MEDICAL MARIJUANA AND THE OPIOID CRISIS
Marijuana from the Cannabis plant is classified as a psychoactive drug used for medical or recreational purposes. Although it has been used for decades, in the U.S., it is still illegal under federal law to use and possess marijuana.
Get PDF Sample Brochure of this report at: https://decisionmarketreports.com/request-sample/1247622
Nevertheless, at the state level, policies regarding the medical and recreational use of Cannabis vary greatly, and in many states conflict significantly with federal…
